

TEST PATIENT GUa d`Y`HYgh'BUa Y

DUHY Collected : 00-00-0000

111 H9GH'ROAD TEST SUBURB **@AB =8: 00000000** UR#:0000000

Sex : :

TEST PHYSICIAN


DR JOHN DOE 111 CLINIC STF 99H 7@-B =7 GI 6I F6 J =7 '' \$\$\$

P: 1300 688 522

E: info@nutripath.com.au A: PO Box 442 Ashburton VIC 3142

HAEMATOLOGY **BLOOD - CITRAT** Result Range Units g/L **FIBRINOGEN** 2.0 - 4.5 2.4 BIOCHEMISTRY BLOOD - SERUM Result Range Units 0.0 - 5.5 **CHOLESTEROL** 4.9 mmol/L TRIGLYCERIDES 0.6 0.2 - 1.5 mmol/L HDL(Protective) 1.5 > 1.0 mmol/L 0.5 - 3.5 mmol/L LDL(Atherogenic) 3.0 LDL/HDL RATIO (Risk Factor) 2.0 0.0 - 3.6 Lipoprotein (a) **216 *H** 0.0 - 75.0 nmol/L 0.60 - 1.40 **Apolipoprotein B** 0.81 g/L **Apolipoprotein A-1** 1.10 - 1.80 g/L 1.44 RATIO (APO B / APO A-1) 0.45 - 1.25 0.56 HOMOCYSTEINE 9.0 5.0 - 12.0 umol/L **C-REACTIVE PROTEIN** <1.0 0.0 - 5.0 mg/L LIPOSCREEN LDL Subfractions2 Very Low Density Lipoprotein (VLDL) 0.8 *H 0.1 - 0.6 mmol/L Intermediate Density Lipoprotein (IDL-1) 0.3 0.1 - 0.6 mmol/L Intermediate Density Lipoprotein (IDL-2) 0.7 *H 0.1 - 0.4 mmol/L Intermediate Density Lipoprotein (IDL-3) 1.1 *H 0.1 - 0.6 mmol/L Low Density Lipoprotein (LDL-1) 0.6 0.1 - 1.5 mmol/L mmol/L Low Density Lipoprotein (LDL-2) 0.1 - 0.8 0.1 • Low Density Lipoprotein (LDL-3) 0.0 *L 0.1 - 0.2 mmol/L Low Density Lipoprotein (LDL-4) 0.00 0.00 - 0.01 mmol/L Low Density Lipoprotein (LDL-5) 0.00 0.00 - 0.01 mmol/L Low Density Lipoprotein (LDL-6) 0.00 - 0.01 mmol/L 0.00 0.00 - 0.01 mmol/L Low Density Lipoprotein (LDL-7) 0.00 LDL Phenotype Pattern Type A

Mean Particle Size



*Beterence ranges derived mon 125 serum semples the root the NCEP ATFIII guidelines for desimble light status: *LDLC is comprised of the sum of hotelearten in MB dance of through As are well as all the subtractions (H) Result is above upper limit of reference range (L) Result is below lower limit of reference range

(*) Result outside normal reference range

Page 1 of 3

Final Report



TEST PATIENT TEST PHYSICIAN DR JOHN DOE GUa d`Y HYgh BUa Y Sex : : 111 CLINIC STF 99H DUhY Collected : 00-00-0000 111 H9GH ROAD TEST SUBURB @AB =8: 0000000 UR#:0000000

P: 1300 688 522 E: info@nutripath.com.au A: PO Box 442 Ashburton VIC 3142

LIPOSCREEN Comments

RESULT INTERPRETATION

The Liposcreen LDL Subractions test provides a superior indicator for Coronary Artery Disease (CAD) risk than other conventionally available lipid profiles. Many individuals with normal LDL and HDL cholesterol levels remain at risk from CAD as these conventional tests do not convey the detail of the CAD risk. Liposcreen additionally quantifies the different subfractions.

Liposcreen clearly identifies a patient's LDL phenotype profile;

This patient has a profile indicative of Type A, which is deemed normal.

Туре А	Deemed a normal profile. Predominance of large/buoyant (less atherogenic) LDL subclasses (LDL 1 and 2). Mean Particle Size of > 263 Angstrom (A). Elevated Cholesterol, Normal Triglycerides, Elevated Apo B	
Туре В	Deemed an ABNORMAL profile. Predominance of small/dense (more atherogenic) LDL subclasses (LDL3, 4, 5, 6, 7). Mean Particle Size of < 258 Angstrom (A). Raised Cholesterol, Raised Triglycerides, Raised VLDL, Low HDLC This profile is the designated atherogenic lipoprotein phenotype, consistent with an increased risk of CAD. It is also It is also characteristically prevalent in insulin-resistant states such as Metabolic Syndrome and Type 2 Diabetes mellitus.	

Follow up Liposcreen testing, for this patient, is recommended in 12 months.

Lipid Profile Comment

LIPOPROTEIN(a) ELEVATED: Consists of an LDL bound to Apolipoprotein component. Causes atherothrombogenesis and strongly associated with peripheral and coronary events.

Consider the following possible causes: Genetic predisposition, Excessive intake of partially hydrogenated oils/fats, low-fibre, low vegetable-based diet, Hypothyroidism, Post-Menopausal elevation, Diabetes, particularly with central obesity, Chronic renal insufficiency, Simvistatin Therapy, Compounded likelihood of CVD if also high LDL and/or total Cholesterol.

Consider the following actions: Aerobic Exercise, Dietary modification, 1 g TID Niacin OR inositol hexaniacinate (non-flush if availalable), CoQ10, L-lysine, proline, HRT if indicated, Magnesium, Coronary vasodilator therapy - as elevated Lp(a) may impair normal vasodilation mechanisms. Vitamin C, L-Lysine and Vitamin E are also beneficial.

Increased HDL levels appear to reduce the threat posed by high levels of Lp(a).

Lp(a) COMMENT: For Lp(a) levels > 0.30 g/L the relative risk of MI is 1.75 compared to patients with Lp(a) below this level. Lp(a) is an acute phase reactant and the level is elevated in acute illness.

	TEST PATIENT	TEST PHYSICIAN
	GUa d`Y`HYgh`BUa Y	DR JOHN DOE
NutriPATH	Sex : :	111 CLINIC STF 99H
NULTIPATH	DUHY Collected : 00-00-0000	7@=B=7 GI 6I F6 J =7 '' \$\$\$
Integrative Pathology Services	111 H9GH ROAD TEST SUBURB	
	@AB =8: 00000000 UR#:0000000	
P: 1300 688 522		
E: info@nutripath.com.au A: PO Box 442 Ashburton VIC 3142		

BIOCHEMISTRY						
BLOOD - FL. OXA	Result	Range	Units			
GLUCOSE (FASTING)	4.8	3.5 - 6.0	mmol/L			

Tests ordered: FIB,FGLU,CVP,IMPEI,CFee,LIPOSCRN2